Uptake on Annex 15 Slow in the Asia-Pacific Region
This article was originally published in The Gold Sheet
Executive Summary
Widespread adoption of PIC/S GMP guidelines in the Asia-Pacific region has not necessarily translated into uptake of Annex 15 and the lifecycle approach to process validation that has taken hold in the US and the EU, a consultant tells ISPE meeting.
You may also be interested in...
Asia-Pacific Region Begins Adopting Lifecycle Approaches To Process Validation
Pharmaceutical manufacturers in India should be aware that inspectors may be looking to see that lifecycle approaches to process validation have been used in their systems with the country’s adoption of a WHO guideline on process validation. ASEAN is also about to issue guidance that tells manufacturers how to design a lifecycle approach to validating vaccine manufacturing processes.
Program Participants Urge The FDA To Adopt Some Pharmaceutical Quality Metrics And Avoid Others
Site-based metrics praised; lot acceptance rates, invalidated OOS rates discouraged. Agency official admits some proposed metrics were “not the best.”
EU GMP Annex I Is A Top Priority For EMA While Industry Has Lingering Concerns
Questions about contamination control strategy raised as European Medicines Agency makes EU GMP Annex I revision a top priority in its 2021 work plan.